Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xenetic Biosciences Inc
(NQ:
XBIO
)
4.250
UNCHANGED
Streaming Delayed Price
Updated: 3:56 PM EDT, Oct 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Xenetic Biosciences Inc
< Previous
1
2
Next >
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
September 11, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Announces Executive Leadership Transition
May 22, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
May 10, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
March 22, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
January 17, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
October 11, 2023
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results
August 11, 2023
Via
ACCESSWIRE
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
July 05, 2023
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
November 10, 2023
Via
ACCESSWIRE
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
May 12, 2023
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development
May 04, 2023
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
May 03, 2023
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update
March 23, 2023
Via
ACCESSWIRE
Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event
March 16, 2023
Via
ACCESSWIRE
Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event
January 05, 2023
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
August 12, 2022
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
April 11, 2023
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy
January 17, 2023
Via
ACCESSWIRE
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
January 11, 2023
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform
November 16, 2022
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics
October 11, 2022
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board
October 04, 2022
Via
ACCESSWIRE
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022
Via
ACCESSWIRE
Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer
August 02, 2022
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
July 07, 2022
FRAMINGHAM, MA / ACCESSWIRE / July 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology...
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
JTC Team to Host Virtual Investor Innovation in Oncology Featuring Xenetic Biosciences
June 02, 2022
- Live video webcast with moderated roundtable with members of the Xenetic leadership team and surgical oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ET -
From
JTC Team, LLC
Via
AccessWire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.